What is GlaxoSmithKline plc's current stock price?

GlaxoSmithKline plc (GSK) currently trades at USD 56.69. Track real-time price changes and historical performance on AllInvestView.

What is GlaxoSmithKline plc's dividend yield?

GlaxoSmithKline plc has a dividend yield of 2.87623900%. The 5-year average dividend yield is 4.77000000%. Track dividend payments and income with AllInvestView.

What sector is GlaxoSmithKline plc in?

GlaxoSmithKline plc operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

GlaxoSmithKline plc GSK Open GlaxoSmithKline plc in new tab

56.69 USD

P/E

14.62

EPS

3.71

Yield

2.88%

Safety Score

P/B

10.02

ROE

43.31

Beta

0.32

Target Price

57.48 USD

GlaxoSmithKline plc

🧾 Earnings Recap – Q3 2025

GSK's Q3 2025 results reflect robust growth with total sales increasing by 8%, driven by strong performance in specialty medicines, and a significant upgrade in guidance for the year. The company also reported positive cash generation and progress in R&D, highlighting its commitment to innovation and sustainability.

Total sales reached GBP 8.5 billion in Q3, up 8% year-over-year, with specialty medicines growing 16%.
Core operating profit increased by 11%, and core EPS rose 14% to 55p.
GSK secured four FDA approvals this year, including for BLENREP, and expects to launch a low-carbon version of Ventolin in 2026.
Cash generation stood at GBP 6.3 billion year-to-date, supporting ongoing investments and a quarterly dividend of 16p.
Full-year specialty guidance has been upgraded from low teens to mid-teens percentage growth.

View full recap page

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for GlaxoSmithKline plc (GSK)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

GlaxoSmithKline plc Analysis (GSK)

United Kingdom Health Care Official Website Stock

Is GlaxoSmithKline plc a good investment? GlaxoSmithKline plc (GSK) is currently trading at 56.69 USD. Market analysts have a consensus price target of 57.48 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 14.62. This relatively low multiple may signal that GlaxoSmithKline plc is undervalued compared to historical market norms.

Earnings Schedule: GlaxoSmithKline plc is expected to release its next earnings report on April 29, 2026. The market consensus estimate for Forward EPS is 5.13.

For income investors, GlaxoSmithKline plc pays a dividend yield of 2.88%. With a payout ratio of 45%, the dividend appears sustainable.

Investor FAQ

Does GlaxoSmithKline plc pay a dividend?

Yes, it pays an annual dividend of 0.62 USD (2.88% yield).

What asset class is GlaxoSmithKline plc?

GlaxoSmithKline plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 29, 2026. The company currently has a trailing EPS of 3.71.

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Exchange Ticker

NYQ (United States) GSK

Dividend Yield

2.88% (5y avg: 4.77%)

Annual Dividends

0.62 USD

Next ex. div date

Feb. 20, 2026

Payout Ratio

44.86%

Historical Dividends

Year	Total Dividends
2027	0.40 USD
Jan. 14, 2027 (estimated)	0.3951
2026	1.72 USD
Oct. 8, 2026 (estimated)	0.4100
July 9, 2026 (estimated)	0.4029
April 9, 2026	0.4781
Jan. 8, 2026	0.4256
2025	1.64 USD
Oct. 9, 2025	0.4281
July 10, 2025	0.4291
April 10, 2025	0.4076
Jan. 9, 2025	0.3769
2024	1.54 USD
Oct. 10, 2024	0.3928
July 11, 2024	0.3843
April 11, 2024	0.4049
Jan. 11, 2024	0.3564
2023	1.41 USD
Oct. 12, 2023	0.3435
July 13, 2023	0.3609
April 13, 2023	0.3330
Jan. 12, 2023	0.3695
2022	1.84 USD
Oct. 6, 2022	0.3830
July 1, 2022	0.3414
April 7, 2022	0.6035
Jan. 13, 2022	0.5168
2021	2.49 USD
Oct. 7, 2021	0.5175
July 8, 2021	0.6578
April 8, 2021	0.7958
Jan. 14, 2021	0.5167
2020	2.15 USD
Oct. 8, 2020	0.4929
July 9, 2020	0.5901
April 9, 2020	0.5670
Jan. 9, 2020	0.4998
2019	2.40 USD
Oct. 10, 2019	0.5823
July 11, 2019	0.5913
April 11, 2019	0.7463
Jan. 10, 2019	0.4839
2018	2.41 USD
Oct. 11, 2018	0.6195
July 12, 2018	0.6291
April 12, 2018	0.6517
Jan. 11, 2018	0.5142
2017	2.02 USD
Oct. 12, 2017	0.5010
July 13, 2017	0.4904
April 13, 2017	0.5712
Jan. 12, 2017	0.4621
2016	2.74 USD
Oct. 13, 2016	0.4665
July 14, 2016	0.5002
April 14, 2016	1.2266
Jan. 14, 2016	0.5490
2015	2.62 USD
Oct. 1, 2015	0.5769
July 9, 2015	0.5862
April 9, 2015	0.6952
Jan. 8, 2015	0.7663
2014	2.65 USD
Oct. 2, 2014	0.6482
July 10, 2014	0.6400
April 10, 2014	0.7496
Jan. 9, 2014	0.6161
2013	2.65 USD
Oct. 3, 2013	0.6915
July 11, 2013	0.6878
April 11, 2013	0.6895
Jan. 3, 2013	0.5790
2012	2.58 USD
Oct. 4, 2012	0.5279
July 5, 2012	0.6864
April 12, 2012	0.8213
Jan. 5, 2012	0.5430
2011	2.43 USD
Oct. 6, 2011	0.5211
July 7, 2011	0.6579
April 7, 2011	0.6153
Jan. 6, 2011	0.6342
2010	1.98 USD
Oct. 7, 2010	0.4573
July 8, 2010	0.4603
April 8, 2010	0.5737
Jan. 7, 2010	0.4900
2009	1.95 USD
Oct. 8, 2009	0.5762
July 9, 2009	0.4093
April 9, 2009	0.4946
Jan. 8, 2009	0.4748
2008	2.35 USD
Oct. 9, 2008	0.5191
July 10, 2008	0.5186
April 10, 2008	0.7841
Jan. 10, 2008	0.5326
2007	2.09 USD
Oct. 11, 2007	0.4947
July 12, 2007	0.4807
April 12, 2007	0.5516
Jan. 4, 2007	0.5631
2006	1.84 USD
Oct. 5, 2006	0.5079
July 6, 2006	0.4915
April 6, 2006	0.4875
Jan. 5, 2006	0.3552
2005	1.54 USD
Oct. 6, 2005	0.3478
July 7, 2005	0.3801
April 7, 2005	0.4444
Jan. 6, 2005	0.3652
2004	1.67 USD
Sept. 30, 2004	0.3659
July 1, 2004	0.3528
April 15, 2004	0.6499
Jan. 6, 2004	0.3002
2003	1.44 USD
Oct. 2, 2003	0.2864
July 3, 2003	0.2851
April 17, 2003	0.5234
Jan. 3, 2003	0.3465
2002	1.42 USD
Oct. 3, 2002	0.3504
July 5, 2002	0.3245
April 18, 2002	0.4279
Jan. 3, 2002	0.3198
2001	1.37 USD
Oct. 4, 2001	0.3183
July 5, 2001	0.3233
April 27, 2001	0.7314
2000	1.28 USD
Oct. 26, 2000	0.5645
June 5, 2000	0.7195
1999	1.43 USD
Oct. 12, 1999	0.6738
June 1, 1999	0.7517
1998	1.27 USD
Oct. 13, 1998	0.6204
June 1, 1998	0.6509
1997	1.22 USD
Dec. 2, 1997	0.6138
May 30, 1997	0.6065
1996	0.93 USD
Oct. 11, 1996	0.4646
May 30, 1996	0.4608
1995	0.95 USD
Nov. 2, 1995	0.6296
April 20, 1995	0.3180
1994	1.10 USD
Sept. 23, 1994	0.7483
March 14, 1994	0.3519
1993	0.35 USD
Sept. 24, 1993	0.0569
March 5, 1993	0.2913
1992	0.78 USD
Sept. 21, 1992	0.4774
Feb. 28, 1992	0.3013
1991	1.11 USD
Sept. 16, 1991	0.7523
March 15, 1991	0.3580
1990	0.92 USD
Sept. 24, 1990	0.6218
March 30, 1990	0.2962
1989	0.62 USD
Oct. 5, 1989	0.4384
April 7, 1989	0.1854
1988	0.26 USD
Nov. 18, 1988	0.1197
April 18, 1988	0.1442
1987	0.36 USD
Nov. 20, 1987	0.2785
May 15, 1987	0.0824
1986	0.45 USD
Nov. 21, 1986	0.3295
May 8, 1986	0.1216
1985	1.24 USD
Nov. 22, 1985	0.9227
May 9, 1985	0.3217
1984	0.45 USD
Nov. 26, 1984	0.4520

Yearly aggregated dividends

Dividends

GlaxoSmithKline plc
Apr 09, 2026 Upcoming

Dividend
0.4781 USD

GlaxoSmithKline plc
Jan 08, 2026 Paid

Dividend
0.42561 USD

GlaxoSmithKline plc
Oct 09, 2025 Paid

Dividend
0.42812 USD

GlaxoSmithKline plc
Jul 10, 2025 Paid

Dividend
0.42909 USD

Historical Split Corporate Actions

Split Date	Split Ratio to 1
July 19, 2022	0.800000
July 22, 2022	1.230000
Nov. 12, 1991	2.000000
Jan. 27, 1986	2.000000
Feb. 22, 1983	2.000000
Feb. 13, 1980	2.000000

Trades

Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Community Discussion

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: support@allinvestview.com

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.

GlaxoSmithKline plc GSK Open GlaxoSmithKline plc in new tab

GlaxoSmithKline plc

Key Metrics

Growth

Estimates

Dividend

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

GlaxoSmithKline plc Analysis (GSK)

Investor FAQ

Company Profile

Dividend Yield

Annual Dividends

Next ex. div date

Payout Ratio

Historical Dividends

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

GlaxoSmithKline plc GSK Open GlaxoSmithKline plc in new tab

Key Metrics

Growth

Estimates

Dividend

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

GlaxoSmithKline plc Analysis (GSK)

Investor FAQ

Company Profile

Dividend Yield

Annual Dividends

Next ex. div date

Payout Ratio

Historical Dividends

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Notifications